APA (7th ed.) Citation

TFW, S., M, M., M, P., M, B., G, F., P, G., . . . WSC, E. (2026). Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): An international, retrospective cohort study. The Lancet. Oncology, 27(3), 383. https://doi.org/10.1016/S1470-2045(25)00717-X

Chicago Style (17th ed.) Citation

TFW, Soeterik, et al. "Nomogram-based Risk Classification for Predicting Response to Metastasis-directed Stereotactic Body Radiotherapy in PSMA PET-staged Oligorecurrent Prostate Cancer (PORTAL): An International, Retrospective Cohort Study." The Lancet. Oncology 27, no. 3 (2026): 383. https://doi.org/10.1016/S1470-2045(25)00717-X.

MLA (9th ed.) Citation

TFW, Soeterik, et al. "Nomogram-based Risk Classification for Predicting Response to Metastasis-directed Stereotactic Body Radiotherapy in PSMA PET-staged Oligorecurrent Prostate Cancer (PORTAL): An International, Retrospective Cohort Study." The Lancet. Oncology, vol. 27, no. 3, 2026, p. 383, https://doi.org/10.1016/S1470-2045(25)00717-X.